MacroGenics Announces Preliminary Clinical Results from Phase 1 Study of MGC018 to be Presented at ASCO Annual Meeting
May 19, 2021 17:05 ET
|
MacroGenics, Inc.
Dose escalation: anti-tumor activity observed in melanoma (including one confirmed partial response) and in mCRPC patientsCohort expansion in mCRPC: 11/22 (50%) patients have ≥ 50% PSA reduction;...
Global Immuno-Oncology Assays Market (2021 to 2026) - Growing Significance of Companion Diagnostics Presents Opportunities
May 14, 2021 05:23 ET
|
Research and Markets
Dublin, May 14, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Assays Market by Product & Service (Consumables, Instruments, Software), Technology (PCR, NGS, Immunoassay), Cancer Indications...
How to Check Your Nails for Melanoma; American Academy of Dermatology
May 11, 2021 14:00 ET
|
American Academy of Dermatology
ROSEMONT, Ill., May 11, 2021 (GLOBE NEWSWIRE) -- When checking the body for signs of skin cancer, many people may only think to check their skin. However, board-certified dermatologists from the...
New American Academy of Dermatology Survey Finds One-Third of Americans Fail Basic Quiz on Skin Cancer and Sun Exposure
April 27, 2021 14:52 ET
|
American Academy of Dermatology
ROSEMONT, Ill., April 27, 2021 (GLOBE NEWSWIRE) -- In a recent survey of 1,000 U.S. adults, the American Academy of Dermatology found that one-third of Americans lack a basic understanding of skin...
Global Immuno-Oncology Market Report 2021-2026: Merck's Keytruda (Pembrolizumab) Leads the Market
March 29, 2021 06:53 ET
|
Research and Markets
Dublin, March 29, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology - Market Analysis, Trends, Opportunities and Unmet Needs - Thematic Research" report has been added to ResearchAndMarkets.com's...
Idera Pharmaceuticals Announces Results From ILLUMINATE-301 Trial of Tilsotolimod + Ipilimumab in anti-PD-1 Refractory Advanced Melanoma
March 18, 2021 16:15 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., March 18, 2021 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA; the “Company”) today is announcing that ILLUMINATE-301, the Company’s pivotal registration trial of...
$135 Billion Immuno-Oncology Markets, 2024
January 07, 2021 08:13 ET
|
Research and Markets
Dublin, Jan. 07, 2021 (GLOBE NEWSWIRE) -- The "Immuno-Oncology Market, by Type (mAb (Naked, Conjugate), Cancer Vaccines, Immune Checkpoint Inhibitors (PD-1, PD-L1, CTLA-4)), by Application (Lung,...
Idera Pharmaceuticals Announces $5.0 Million in Further Proceeds from Private Placement of up to $20.7 Million
December 15, 2020 08:05 ET
|
Idera Pharmaceuticals, Inc.
EXTON, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA) today announced the closing of a second tranche under its April 7, 2020, securities purchase agreement (the...
Idera Pharmaceuticals to Present Tilsotolimod Data at ESMO Virtual Congress 2020
September 15, 2020 07:18 ET
|
Idera Pharmaceuticals, Inc.
Final data from ILLUMINATE-204 trial in advanced melanoma and final results from ILLUMINATE-101 trial in refractory solid tumors to be presentedAbbVie to present a trial-in-progress poster of ABBV-368...
How To Prevent And Treat Common Summer Rashes; American Academy of Dermatology
August 11, 2020 14:30 ET
|
American Academy of Dermatology
ROSEMONT, Ill., Aug. 11, 2020 (GLOBE NEWSWIRE) -- As the coronavirus continues to spread throughout the country, many people may find themselves spending more time outdoors for a much-needed change...